A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib, Trastuzumab, Docetaxel|DRUG: Placebo, Trastuzumab, Docetaxel
Sponsor: Jiangsu HengRui Medicine Co., Ltd.